| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMPR2 |
| Uniprot No | Q13873 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-151aa |
| 氨基酸序列 | SQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGD INLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVN FTENFPPPDTTPLSPPHSFNRDETIVDHHHHHH |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMPR2重组蛋白的3篇参考文献示例(文献信息为示例性质，非真实存在)：
1. **文献名称**：*Recombinant BMPR2 Extracellular Domain Attenuates Pulmonary Hypertension in Rats*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌表达系统制备重组BMPR2胞外结构域蛋白，发现其在肺动脉高压大鼠模型中能够恢复BMP信号通路活性，抑制肺血管重塑，为治疗提供潜在策略。
2. **文献名称**：*Structural and Functional Analysis of BMPR2 Kinase Domain Using Recombinant Protein Expression*
**作者**：Chen L, et al.
**摘要**：利用昆虫细胞系统表达并纯化BMPR2激酶结构域重组蛋白，通过晶体结构解析和体外激酶实验，揭示了其磷酸化机制及与配体结合的构象变化。
3. **文献名称**：*BMPR2 Mutant Recombinant Proteins Reveal Loss-of-Function Mechanisms in Hereditary PAH*
**作者**：Wang Y, et al.
**摘要**：构建携带遗传性肺动脉高压(PAH)相关突变的BMPR2重组蛋白，发现突变导致蛋白稳定性下降及Smad信号传导缺陷，阐明了疾病发生的分子机制。
(注：以上文献为模拟内容，实际引用需查询PubMed、Web of Science等数据库获取真实文献。)
BMPR2 (Bone Morphogenetic Protein Receptor Type II) is a transmembrane serine/threonine kinase receptor belonging to the transforming growth factor-beta (TGF-β) superfamily. It plays a critical role in mediating cellular responses to bone morphogenetic proteins (BMPs), which regulate diverse processes including cell differentiation, apoptosis, and tissue development. The BMPR2 gene, located on chromosome 2q33. encodes a protein with an extracellular ligand-binding domain, a transmembrane domain, and an intracellular kinase domain.
Mutations in BMPR2 are strongly associated with heritable pulmonary arterial hypertension (HPAH), a rare but severe vascular disorder characterized by elevated pulmonary artery pressure and right heart failure. Over 70% of familial PAH cases and ~20% of idiopathic PAH cases involve BMPR2 mutations, leading to dysfunctional BMP signaling and vascular remodeling. This has spurred interest in recombinant BMPR2 protein as a research tool and potential therapeutic agent.
Recombinant BMPR2 proteins are typically produced in mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications. These proteins often include soluble extracellular domains or full-length constructs with tags (e.g., Fc or His tags) for purification and detection. Researchers use them to study BMP signaling pathways, screen for mutation-specific drug candidates, or develop ligand-binding assays.
Recent studies explore BMPR2 recombinant proteins as "decoy receptors" to modulate BMP signaling or as gene therapy vectors to restore BMPR2 function in PAH models. Challenges remain in optimizing bioavailability and tissue-specific targeting, but ongoing advances in protein engineering continue to enhance their therapeutic potential. Understanding BMPR2's structure-function relationships through recombinant variants remains pivotal for unraveling PAH pathogenesis and designing precision therapies.
×
